Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 171,806
  • Shares Outstanding, K 188,798
  • Annual Sales, $ 8,950 K
  • Annual Income, $ -21,490 K
  • 60-Month Beta 1.26
  • Price/Sales 18.98
  • Price/Cash Flow N/A
  • Price/Book 2.60
Trade LCTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.14
  • Most Recent Earnings $-0.03 on 08/08/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.080 on 12/15/03
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 289.75% ( -257.21%)
  • Historical Volatility 54.86%
  • IV Percentile 43%
  • IV Rank 16.67%
  • IV High 1,295.13% on 05/22/24
  • IV Low 88.68% on 09/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 333
  • Volume Avg (30-Day) 179
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 3,657
  • Open Int (30-Day) 5,007

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.04
  • Number of Estimates 3
  • High Estimate -0.03
  • Low Estimate -0.05
  • Prior Year -0.04
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8301 +9.63%
on 09/06/24
0.9700 -6.19%
on 09/23/24
+0.0105 (+1.17%)
since 09/04/24
3-Month
0.7665 +18.72%
on 08/14/24
1.1500 -20.87%
on 07/23/24
-0.0085 (-0.93%)
since 07/03/24
52-Week
0.7665 +18.72%
on 08/14/24
1.6100 -43.48%
on 03/28/24
-0.2900 (-24.17%)
since 10/04/23

Most Recent Stories

More News
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report...

LCTX : 0.9100 (+1.23%)
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging...

LCTX : 0.9100 (+1.23%)
Lineage to Present at 2023 AAPS National Biotechnology Conference

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley,...

LCTX : 0.9100 (+1.23%)
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation...

LCTX : 0.9100 (+1.23%)
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a...

LCTX : 0.9100 (+1.23%)
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating...

LCTX : 0.9100 (+1.23%)
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging...

LCTX : 0.9100 (+1.23%)
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report...

LCTX : 0.9100 (+1.23%)
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX ), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body,...

LCTX : 0.9100 (+1.23%)
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on its auditory...

LCTX : 0.9100 (+1.23%)

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 0.9582
2nd Resistance Point 0.9446
1st Resistance Point 0.9273
Last Price 0.9100
1st Support Level 0.8964
2nd Support Level 0.8828
3rd Support Level 0.8655

See More

52-Week High 1.6100
Fibonacci 61.8% 1.2878
Fibonacci 50% 1.1883
Fibonacci 38.2% 1.0887
Last Price 0.9100
52-Week Low 0.7665

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar